Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus

JAMA

Volumn 295, Issue 5, 2006, Pages 527-535

  Burt, Richard K ^a   Traynor, Ann ^a,b   Statkute, Laisvyde ^a   Barr, Walter G ^a   Rosa, Robert ^a   Schroeder, James ^a   Verda, Larissa ^a   Krosnjar, Nela ^a   Quigley, Kathleen ^a   Yaung, Kimberly ^a   Villa, Marcello ^a   Takahashi, Miyuki ^a   Jovanovic, Borko ^a   Oyama, Yu ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMINOGLYCOSIDE; AMPHOTERICIN B LIPID COMPLEX; ANTINUCLEAR ANTIBODY; CEFEPIME; CIPROFLOXACIN; COMPLEMENT COMPONENT C3; CONTRAST MEDIUM; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DALTEPARIN; DIURETIC AGENT; DOUBLE STRANDED DNA ANTIBODY; ENOXAPARIN; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LEVOFLOXACIN; LOW MOLECULAR WEIGHT HEPARIN; PENTAMIDINE; PREDNISONE; RITUXIMAB; THYMOCYTE ANTIBODY; VALACICLOVIR; VORICONAZOLE; WARFARIN;

ADULT; ARTHRALGIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTEREMIA; BACTERIAL ENDOCARDITIS; BONE MARROW APLASIA; BRAIN VASCULITIS; BRONCHOSCOPY; CD34 SELECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOPRESERVATION; CYTOMEGALOVIRUS INFECTION; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG SAFETY; DYSPNEA; ESOPHAGOSCOPY; ESOPHAGUS CANDIDIASIS; FEMALE; FEVER; FOLLOW UP; FUNCTIONAL ASSESSMENT; GRAFT SURVIVAL; HEMODIALYSIS; HEMOPHILIA A; HERPES ZOSTER; HORSE; HUMAN; HYPERTENSION; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOSUPPRESSIVE TREATMENT; INFUSION; INJURY; KIDNEY FAILURE; KIDNEY FUNCTION; LIFE; LUNG DIFFUSION CAPACITY; LUNG EDEMA; LUNG FUNCTION; MALE; MORTALITY; MUCORMYCOSIS; MYALGIA; NEPHRITIS; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PANCYTOPENIA; PERIPHERAL BLOOD STEM CELL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROBABILITY; RASH; RECURRENT DISEASE; RECURRENT INFECTION; REFRACTORY PERIOD; RELAPSE; RISK ASSESSMENT; SCORING SYSTEM; SEPSIS; SEROLOGY; STANDARD; STEM CELL MOBILIZATION; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYCARDIA; THREAT; THROMBUS; TIME SERIES ANALYSIS; UNITED STATES; UNIVERSITY HOSPITAL; URIC ACID NEPHROPATHY; VIREMIA; VISCERA;

EID: 32044473487     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.295.5.527     Document Type: Article

References (36)

1. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus: results from a single center, II: predictor variables for mortality. J Rheumatol. 1995;22:1265-1267.
2. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period: a multicenter prospective study of 1,000 patients: European Working Party on Systemic Lupus Erythematosus. Medicine. 1999;78:167-175.
3. Austin HA III, Klippel JH, Balow JE, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314:614-619.
4. Bansal VK, Beto JA. Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis. 1997;29:193-199.
5. Chan TM, Li FK, Tang CS, et al; Hong Kong-Guangzhou Nephrology Study Group. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med. 2000;343:1156-1162.
6. Takada K, Illei GG, Boumpas DT. Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus. 2001;10:154-161.
7. Esdaile JM. Prognosis in systemic lupus erythematosus. Springer Semin Immunopathol. 1994;16:337-355.
8. Goldblatt F, Isenberg DA. New therapies for systemic lupus erythematosus. Clin Exp Immunol. 2005;140:205-212.
9. Burt RK, Verda L, Oyama Y, Statkute L, Slavin S. Non-myeloablative stem cell transplantation for autoimmune diseases. Springer Semin Immunopathol. 2004;26:57-69.
10. Ikehara S, Good RA, Nakamura T, et al. Rationale for bone marrow transplantation in the treatment of autoimmune diseases. Proc Natl Acad Sci U S A. 1985;82:2483-2487.
11. Snowden JA, Brooks PM, Biggs JC. Haemopoietic stem cell transplantation for autoimmune diseases. Br J Haematol. 1997;99:9-22.
12. Burt RK, Slavin S, Burns W, Marmont A. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation. Blood. 2002;99:768-784.
13. Marmont AM. Stem cell transplantation for severe autoimmune diseases: progress and problems. Haematologica. 1998;83:733-743.
14. Burt RK, Traynor A, Ramsey-Goldman R. Hematopoietic stem cell transplantation for systemic lupus erythematosus. N Engl J Med. 1997;337:1777-1778.
15. Burt RK, Traynor AE, Pope R, et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood. 1998;92:3505-3514.
16. Traynor AE, Schroeder J, Rosa RM, et al. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study. Lancet. 2000;356:701-707.
17. Traynor AE, Barr WG, Rosa RM, et al. Hematopoietic stem cell transplantation for severe and refractory lupus: analysis after five years and fifteen patients. Arthritis Rheum. 2002;46:2917-2923.
18. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42:1309-1311.
19. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum. 2004;50:3418-3426.
20. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum. 1992;35:630-640.
21. Statkute L, Traynor A, Oyama Y, et al. Antiphospholipid syndrome in patients with systemic lupus erythematosus treated by autologous hematopoietic stem cell transplantation. Blood. 2005;106:2700-2709.
22. Jayne D, Passweg J, Marmont A, et al. Autologous stem cell transplantation for systemic lupus erythematosis. Lupus. 2004;13:168-176.
23. Loberiza FR Jr, Zhang MJ, Lee SJ, et al. Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States. Blood. 2005;105:2979-2987.
24. Dubey S, Nityanand S. Involvement of Fas and TNF pathways in the induction of apoptosis of T cells by antithymocyte globulin. Ann Hematol. 2003;82:496-499.
25. Young N, Speck B. Antithymocyte and antilymphocyte globulins: clinical trials and mechanism of action. Prog Clin Biol Res. 1984;148:221-226.
26. Kang I, Park SH. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol. 2003;15:528-534.
27. Salzberger B, Bowden RA, Hackman RC, Davis C, Boeckh M. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood. 1997;90:2502-2508.
28. Euler HH, Harten P, Zeuner RA, Schwab UM. Recombinant human granulocyte colony stimulating factor in patients with systemic lupus erythematosus associated neutropenia and refractory infections. J Rheumatol. 1997;24:2153-2157.
29. Zavala F, Masson A, Hadaya K, et al. Granulocyte-colony stimulating factor treatment of lupus autoimmune disease in MRL-lpr/lpr mice. J Immunol. 1999;163:5125-5132.
30. Gottenberg JE, Roux S, Desmoulins F, Clerc D, Mariette X. Granulocyte colony-stimulating factor therapy resulting in a flare of systemic lupus erythematosus: comment on the article by Yang and Hamilton. Arthritis Rheum. 2001;44:2458-2460.
31. Mills JA. Systemic lupus erythematosus. N Engl J Med. 1994;330:1871-1879.
32. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002;46:2673-2677.
33. Eisenberg R. SLE: rituximab in lupus. Arthritis Res Ther. 2003;5:157-159.
34. Anolik JH, Barnard J, Cappione A, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 2004;50:3580-3590.
35. Willis F, Marsh JC, Bevan DH, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001;114:891-898.
36. Cohen Y, Polliack A, Nagler A. Treatment of refractory autoimmune diseases with ablative immunotherapy using monoclonal antibodies and/or high dose chemotherapy with hematopoietic stem cell support. Curr Pharm Des. 2003;9:279-288.